Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 17, 2018

View Archived Issues

AD brains have splicing problem

Protecting cartilage in arthritis

Insm1 keeps hair cells in 'n' out

Amgen begins first-in-human study of AMG-427 in relapsed or refractory AML

Modest improvements to visual acuity observed following retinal gene therapy for choroideremia

TLR9-targeted oligonucleotide NF-KappaB inhibitor developed for B-cell lymphoma

Evobrutinib shows reduction in disease activity in patients with relapsing MS

Abide Therapeutics initiates phase II study of ABX-1431 in Tourette syndrome

Patient recruitment ongoing in long-term phase III study of SK-1403

Mouse model mimics human tumors for testing MCL-1 inhibitors

First results presented for [177Lu]Lu-DOTA(ZOL) in patients with osteoblastic metastases

Lianyungang Ruzhong Pharmaceutical Co. and collaborators describe new IDO/TDO inhibitors

Heat shock protein 90 inhibitors discovered at Taipei Medical University

Evotec and Ferring enter strategic research alliance to treat fertility and gynecological conditions

Universite Paris Descartes and collaborators patent GRB14/insulin receptor interaction inhibitors

Eiger's phase II study of ubenimex in lower leg lymphedema does not meet endpoints

Shanghai Hengrui Pharmaceutical Co., Jiangsu Hengrui Medicine Co. discover TGFBR1 inhibitors

STING modulators identified at Boehringer Ingelheim

Phase II study of avexitide in post-bariatric hypoglycemia meets key endpoints

Zhejiang Hisun Pharmaceutical Co. patents acetyl-CoA carboxylase inhibitors

Phase III SUNRISE 2 trial of lemborexant in insomnia meets key endpoints

OCLI-070 inhibits osteoclast differentiation in ligature-induced experimental osteolysis

FDA approves Talzenna for germline BRCA-mutated HER2-negative breast cancer

Allergan plans ubrogepant NDA filing following successful outcome of safety studies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...